OUR  PIPELINE

. . . . . .
Next-generation cardiopulmonary disease-targeted inhalation products designed to enhance drug delivery to the lung periphery
Product Development
. . . . . .

Our approach combines Respira’s state-of-the-art AOS™ dry-powder inhaler device and proprietary inhaled drug formulation technologies to enhance dose consistency and drug targeting to the small airways of the lung.

RT234-PAH

. . . . . .

First-in-class inhaled therapy

Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in pulmonary arterial hypertension (PAH) patients (Group 1 in the World Health Organization’s classification of pulmonary hypertension indications). This contrasts with all other current PAH treatments, which are taken according to a chronic treatment regimen and monitored for chronic improvements in outcome measures.

RT234 demonstrated robust safety margins in preclinical testing and was well tolerated in Phase 1 clinical studies, with pharmacokinetic profiles consistent with expectations for a PRN medication.

Respira has received FDA Orphan Drug designation for the active ingredient in RT234 (vardenafil, a potent vasodilator that is FDA-approved in an oral form for a non-PAH indication) for the treatment of PAH and is currently in Phase 2 clinical testing for this indication.

RT234-ILD PH
. . . . . .
Leveraging preclinical and Phase 1 studies of RT234-PAH, Respira is developing RT234-ILD PH as a treatment for patients with Interstitial Lung Disease (WHO Group 3.2 Pulmonary Hypertension) to relieve breathlessness and fatigue and improve exercise capacity resulting from elevated pulmonary artery pressures. RT234-ILD PH is Phase 2 clinical trial-ready.

Learn more about our Phase 2B clinical trial in PAH [here]

vipah_logo_graphic
About Pulmonary Hypertension (PH)
. . . . . .
Pulmonary hypertension is a severe, rare lung disease characterized by high blood pressure in the pulmonary arteries, which deliver blood from the heart to the lungs. The high pressure causes the heart to work harder to pump blood.